Abstract：Objective To study clinical effect of Sitagliptin combined with Insulin Aspart 30 in the treatment of obese type 2 diabetes. Methods Eighty cases of obese type 2 diabetes patients who were admitted to the First People′s Hospital of Hefei from March 2018 to September 2019 were selected for this study. They were divided into the control group and the observation group by random number table method, with 40 cases in each group. The control group was given Insulin Aspart 30, and the observation group was treated with Sitagliptin on the basis of the control group, and both groups were treated continuously for three months. The clinical efficacy, the changes in blood lipids(total cholesterol [TC], triacylglycerol [TG], high density lipoprotein-cholesterol [HDL-C], low density lipoprotein-cholesterol [LDL-C]), blood glucose (fasting blood glucose [FBG], 2-hour postprandial blood glucose [2hPBG], glycated hemoglobin [HbA1c]), body mass index (BMI), uric acid (UA), hypersensitive C-reactive protein (hs-CRP) before and after treatment and adverse reactions were compared between the two groups. Results After treatment, the total effective rate of the observation group (95.00%) was higher than that of the control group (80.00%), the difference was statistically significant (P ＜ 0.05). After treatment, TC, TG and LDL-C levels decreased with HDL-C levels increased in both groups compared with those before treatment, and TC, TG and LDL-C levels in the observation group after treatment were lower than those in the control group, HDL-C level was higher than that in the control group, the differences were statistically significant (P ＜ 0.05). After treatment, FBG, 2hPBG and HbA1c levels decreased in both groups compared with those before treatment, and FBG, 2hPBG and HbA1c levels in the observation group were lower than those in the control group, the differences were statistically significant (P ＜ 0.05). After treatment, BMI, UA, hs-CRP levels decreased in both groups compared with those before treatment, and BMI, UA, hs-CRP levels of the observation group were lower than those of the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the adverse reactions between the two groups (P ＞ 0.05). Conclusion The clinical efficacy of Sitagliptin combined with Insulin Aspart 30 in the treatment of obese type 2 diabetes is outstanding, and the patient′s blood lipid and blood glucose levels are significantly improved, which can effectively reduce the BMI, and it is worthy of clinical promotion.
刘皆 吕芳 王国娟 马维青▲. 西格列汀联合门冬胰岛素30治疗肥胖型2型糖尿病患者的临床效果[J]. 中国医药导报, 2020, 17(24): 75-78.
LIU Jie LYU Fang WANG Guojuan MA Weiqing▲. Clinical effect of Sitagliptin combined with Insulin Aspart 30 in the treatment of obese type 2 diabetes. 中国医药导报, 2020, 17(24): 75-78.
2020, Vol. 17 
京公网安备 11010502046598号